The US FDA would become more involved in pharmaceutical manufacturing business continuity planning under several legislative proposals outlined in the agency’s fiscal year 2020 budget request.
One proposal would give FDA more authority to make application holders for “certain drugs” periodically assess the risk of supply chain disruptions, identify vulnerabilities and develop risk mitigation plans. The...